Germany: Will The Human Genome Soon Be Patented?

Last Updated: 17 January 2001
Article by Martin Grund

Since the anticipated announcement by Craig Venter of Celera Genomics -- relating to the successful sequencing of the human genome -- both scientific and lay people alike have been wondering out loud about the implications of such a historic feat. In particular, there appears to be great concern about the patenting of the human genome, and the potential extraction of this genetic information from the public domain. Of course, these concerns are expressed on a global scale.

The basic prerequisites for obtaining a European or German patent include an invention that is novel, has an inventive step, and finally, the invention must be susceptible to industrial application. This article presents several hypotheticals relating to the patenting of genetic sequences under the European Patent Convention. These hypotheticals represent exemplary situations of whether the above-mentioned prerequisites for a European patent are satisfied, with particular emphasis on the patenting of genetic sequences having known or unknown function.


EXAMPLES

Hypothetical A
The specification of a patent application generally discloses a full or partial sequence of a gene, without specific information directed to the function of the genetic sequence or the resulting amino acid composition. The specification also describes the use of the partial sequence to locate and characterize the corresponding complete gene sequence.

Hypothetical B
The specification of a patent application discloses a complete and/or partial sequence of a gene, the function of this genetic sequence, and the function of the encoded protein. However, the function of the encoded protein is merely speculative and simply based on a homology comparison with known nucleic acids and proteins.

Hypothetical C
As in Hypothetical B, the specification of a patent application discloses a complete and/or partial sequence of a gene in addition to functional information relating to the nucleic acid or the encoded protein. However, in this example, the function of the genetic sequence or encoded protein has been characterized using accepted scientific approaches.


DISCUSSION

Result of Hypothetical A
Pursuant to Rule 23e(2) EPC 1, a patent application that discloses and claims a full or partial sequence of a gene may qualify as a patentable invention. However, Rule 23e(1) EPC qualifies this rule by stating that the finding of a genetic sequence does not constitute a patentable invention by itself. In other words, the mere disclosure of a genetic sequence does not provide subject matter that qualifies as a technical teaching. Therefore, this disclosure fails to constitute a patentable invention. (See Art. 52(1) EPC which provides the basic definition of patentability). Furthermore, Rule 23e(3) EPC requires that the invention provide industrial applicability, i.e. a complete genetic sequence or a partial sequence of a gene must be described specifically. (See Art. 57 EPC). Thus, in the present hypothetical, at least two essential requirements for a European patent grant fail to be satisfied.

Result of Hypothetical B
In contrast to the facts of Hypothetical A, the example presented in Hypothetical B constitutes patentable subject matter under the EPC. For example, the complete and/or partial sequence of a gene, and the function of this sequence and resulting encoded protein, constitute patentable subject matter under Art. 52(1) EPC (and associated Rule 23e(1) EPC). In addition, the prerequisite of industrial applicability is fulfilled, as well as novelty (under Art. 54 EPC) if the described sequence has not been published or described in any publication or patent.

However, in this example, the essential requirement of an inventive step (see Art. 56 EPC) presents an obstacle in obtaining the patent grant. Generally, there is no inventive step for a technical advancement which is obvious to the ordinary person skilled in the art, e.g. if the advancement is merely routine work for a corresponding scientist in the respective technical area. In Hypothetical B, the patent application resolves the speculative function of the genetic sequence or encoded protein by homology comparison with known nucleic acids and proteins. Such comparisons are routinely performed by using widely available computer programs for the prediction of protein structure derived from genetic sequences. Therefore, this requisite step to identify function fails to constitute an inventive step because of the obvious and routine nature of this critical task. Therefore, this patent application would fail to satisfy the essential prerequisite of an inventive step under Article 56 EPC and cannot result in a granted patent.

Result of Hypothetical C
Similar to the result in Hypothetical B, the example presented in Hypothetical C constitutes patentable subject matter under the EPC. For example, the complete and/or partial sequence of a gene, and the function of this sequence and encoded protein, constitute patentable subject matter under Art. 52(1) EPC (and associated Rule 23e(1) EPC). In addition, the prerequisite of industrial applicability and novelty (under Art. 54 EPC) are similarly satisfied.

In the present hypothetical, the essential requirement of an inventive step (see Art. 56 EPC) is the decisive factor for the grant of a patent application which describes the function of a genetic sequence or encoded protein that has been characterized using accepted scientific approaches. The critical question of patentability will apply on a case-by-case basis, depending on how much information is already known about the genetic or protein sequence and any corresponding function. This notion also applies to any related homologous sequences. For example, no inventive step will be found for a patent application containing known sequences where a function for the corresponding gene or the encoded protein was publicly suggested.

In contrast, an inventive step will likely be found if a new gene and its corresponding function, or the function of the resulting encoded protein, are described in a patent application where the gene or the resulting encoded protein exhibit only a small degree or no degree of homology to known genes/proteins having a similar function.

Furthermore, an inventive step may likely be found even if the gene sequences and/or protein sequences exhibit a high degree of homology to known sequences, if a different function of the nucleic acid or protein is described or proved. This defined function must be different than would have been expected, or nonobvious in view of any homology comparison using the identified genetic or protein sequences.


CONCLUSION

Although there may be significant effort to secure patents for all human nucleic acid or amino acid sequences, it is unlikely that such patents will be immediately granted. The mere sequencing and the subsequent homology comparison of identified human genomic sequences do not by themselves satisfy the requirements for patentability under the EPC.

However, the recent characterization of the human genetic transcript presents great possibility for inventive concepts and thus, for patent applications. For example, a potentially patentable invention can include an already known sequence that may be modified to produce an unexpectedly high or low activity of the resulting protein. Furthermore, patentable inventions can also be based on using the known genetic sequences for novel medical or diagnostic applications. True, the potential of global commercial exploitation of the human genetic code is unknown, however, the numerous procedural safeguards present in the various patent systems may curtail the swift race to the patent office.




FOOTNOTE

1 Inserted by decision of the Administrative Council of 16.06.1999 (Adaption of the Implementing Regulations of the EPC to the Biotechnology-Guideline (Guideline 98/44/EC) which entered into force on 01.09.99



The information contained in this article is intended only to provide a general guide to the subject matter. Advice from specialists is still recommended for your specific requirement and particular circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions